Gefitinib EGFR inhibitors
systematic review meta-analysis network meta-analysis
 

ZD 1839 - ZD1839 - Iressa      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

lung cancer (metastatic)  

West Japan   gefitinib -
Northeast Japan   gefitinib -
CTONG0806 (Yang), 2013   gefitinib - 96%
NEJ002, 2013     gefitinibcarboplatin-paclitaxel1L -
Maemondo, 2010       gefitinibcarboplatin-paclitaxel2L -
IPASS (Mok), 2009      NCTgefitinibcarboplatin-paclitaxel1L -
IPASS           gefitinibcarboplatin/paclitaxel1L -
WJTOG3405 (Mitsudomi), 2010     gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010     gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010     gefitinibdocetaxel2Lsuggesting-13%-27%
V-15-32 (Maruyama), 2008         gefitinibdocetaxel2Lsuggesting12%-10%
INTEREST (Kim), 2008   gefitinibdocetaxel2Lnegative1%4%
SIGN (Cufer), 2006   gefitinibdocetaxel2Lnegative-3%-6%
IFCT-0301 study (Morère), 2010     gefitinibdocetaxel -
Kris, 2003     gefitinibgefitinib2LLow risk of bias -
First Signal       gefitinibgemcitabine and cisplatin1L -
INTACT 2, 2004     gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1LLow risk of bias -
NCIC CTG BR19 (Goss), 2013     gefitinibplaceboLow risk of bias -
INFORM; C-TONG 0804, 2012      NCTgefitinibplacebo -
EORTC 08021/ILCP 01/03, 2011      NCTgefitinibplacebo2L -
Goss, 2009     gefitinibplacebo1L -
SWOG S0023 (Kelly), 2008     gefitinibplacebo -
ISEL, 2006       gefitinibplacebo2L -
Tsuboi, 2005     gefitinibplacebo -
INTACT 1.     gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1LLow risk of bias -
INVITE (Crinò), 2008      NCTgefitinibvinorelbine1L -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons